摘要
小细胞肺癌是一种高度侵袭性神经内分泌癌,易转移且进展快,耐药率及复发率高。目前的治疗方案对患者的生存获益非常有限。2024年5月16号,美国食品药品监督管理局(FDA)批准tarlatamab上市,为既往接受过一线或二线治疗的小细胞肺癌患者提供了新的治疗方案。临床研究显示本品治疗效果佳且安全性高。本文对其药理作用、药代动力学特征、临床评价、安全性及用法用量进行简要概述。
Small cell lung cancer(SCLC)is a highly invasive neuroendocrine carcinoma that is prone to metastasis and progression,with high rates of drug resistance and recurrence.The current treatment options have limited benefits for patient survival.On May 16,2024,the FDA approved the marketing of tarlatamab,providing a new treatment plan for SCLC patients who have previously received first-line or second-line treatment.Clinical studies have shown that this drug is effctive and safe.This article reviews the pharmacological effects,clinical studies,safety,usage and dosage of tarlatamab.
作者
郑丽
张凯华
孙雪林
ZHENG Li;ZHANG Kaihua;SUN Xuelin(Department of Pharmacy,China Aerospace Science&Industry Corporation 731 Hospital,Beijing 100074,China;Department of Thoracic Surgery,China Aerospace Science&Industry Corporation 731 Hospital,Beijing 100074,China;Department.of Pharmacy,Beijing Hospital,Beijing 100730,China)
出处
《中国药物警戒》
2024年第9期1078-1080,共3页
Chinese Journal of Pharmacovigilance
基金
中央高水平医院临床科研业务费资助(BJ-2023-200)
国家重点研发计划(2020YFC2009001)
七三一医院院级科研基金(2022-QSYN-01)。
